Inspira gets Nasdaq bid-price deficiency notice
Inspira Technologies Oxy B.H.N.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Inspira Technologies Oxy B.H.N. Ltd. received a Nasdaq notice on February 9, 2026 that its ordinary shares are not in compliance with the $1.00 minimum bid price requirement, after trading below that level for 30 consecutive business days.
The notice has no immediate effect on trading, and the shares continue on the Nasdaq Capital Market under symbol IINN. The company has 180 days, until August 10, 2026, for its closing bid price to reach at least $1.00 for ten consecutive business days to regain compliance, with the possibility of a second 180‑day period if additional conditions are met.
If compliance is not restored within the allowed period, Nasdaq may delist the shares. Inspira plans to monitor its share price and consider available options, potentially including a reverse share split, to address the deficiency.
Positive
- None.
Negative
- Nasdaq minimum bid price non-compliance introduces delisting risk if Inspira Technologies cannot lift its ordinary share closing bid price to at least $1.00 for ten consecutive business days within the 180‑day compliance window, or any subsequent extension.
Insights
Nasdaq bid-price deficiency introduces delisting risk but allows time to cure.
Inspira Technologies is currently below Nasdaq’s $1.00 minimum bid for ordinary shares, triggering a formal deficiency notice. This status can affect how some institutional investors view the stock, since many mandate listings on major exchanges such as the Nasdaq Capital Market.
The company has an initial August 10, 2026 deadline, requiring a closing bid of at least $1.00 for ten consecutive business days. Nasdaq may grant another 180‑day period if listing criteria such as market value of publicly held shares are met and the company outlines a cure plan.
Management indicates it will monitor the share price and may use tools like a reverse share split to regain compliance. Actual impact on shareholders will depend on whether the bid price recovers within the current or any extended compliance period described.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Nasdaq notification did Inspira Technologies (IINN) receive?
How long does Inspira Technologies have to regain Nasdaq bid price compliance?
Can Inspira Technologies receive more time beyond August 10, 2026 to cure the deficiency?
What happens if Inspira Technologies cannot meet the Nasdaq bid price requirement?
What steps does Inspira Technologies plan to take regarding the bid price issue?
What business is Inspira Technologies focused on despite the Nasdaq notice?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of February 2026 (Report No. 4)
Commission File Number: 001-40303
Inspira Technologies Oxy B.H.N. Ltd.
(Translation of registrant’s name into English)
2 Ha-Tidhar St.
Ra’anana 4366504, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
☒ Form 20-F ☐ Form 40-F
CONTENTS
On February 12, 2026, Inspira Technologies Oxy B.H.N. Ltd. (the “Company”) issued a press release titled “Inspira Technologies Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Requirement,” a copy of which is furnished as Exhibit 99.1 with this report of foreign private issuer on Form 6-K.
This Report on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (Registration Nos. 333-284308 and 333-289324) and Form S-8 (Registration Nos. 333-259057, 333-277980, 333-285565, 333-290162 and 333-292592), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
| Exhibit No. | ||
| 99.1 | Press Release issued by Inspira Technologies Oxy B.H.N. Ltd. on February 12, 2026, titled “Inspira Technologies Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Requirement.” |
1
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Inspira Technologies Oxy B.H.N. Ltd. | |||
| Date: February 12, 2026 | By: | /s/ Dagi Ben-Noon | |
| Name: | Dagi Ben-Noon | ||
| Title: | Chief Executive Officer | ||
2
Exhibit 99.1
Inspira Technologies Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Requirement
RA’ANANA, Israel, February 12, 2026 -- Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN,IINNW) (“Inspira Technologies” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced that it received a written notification (the “Notification Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) on February 9, 2026, notifying the Company that it is not currently in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2), as the closing bid price of the Company’s ordinary shares (“Ordinary Shares”) was below $1.00 per share for the last 30 consecutive business days.
The Notification Letter has no immediate effect on the listing or trading of the Company’s Ordinary Shares, which will continue to trade on The Nasdaq Capital Market under the symbol “IINN.”
In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a compliance period of 180 calendar days, or until August 10, 2026 (the “Compliance Period”), to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s Ordinary Shares must be at least $1.00 per share for a minimum of ten consecutive business days during the Compliance Period.
If the Company does not regain compliance by August 10, 2026, the Company may be afforded a second 180-calendar day compliance period. To qualify for this additional time, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the minimum bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, including by effectuating a revere share split, if necessary. If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that the Company’s Ordinary Shares will be subject to delisting.
The Company intends to monitor the closing bid price of its Ordinary Shares between now and August 10, 2026, and intends to consider available options to cure the deficiency regain compliance with the Nasdaq minimum bid price requirement within the Compliance Period.
This announcement is made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.
About Inspira Technologies
Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s FDA-cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. For more information, visit: https://inspira-technologies.com.
Forward-Looking Statements
This press release contains express or implied forward-looking statements pursuant to U.S. federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses its ability to regain compliance with the Nasdaq minimum bid price requirement within the applicable Compliance Period, its intention to monitor the trading price of its Ordinary Shares, and its consideration of available options to regain compliance with Nasdaq listing requirements. These forward-looking statements and their implications are based solely on the current expectations of the Company’s management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC’s website at www.sec.gov.
Company Contact
Inspira Technologies
Email: info@inspirao2.com
Phone: +972-9-9664485